Expertise in
5
conditions

Dr. Russell J. Butterfield

Pediatric Neurology
81 North Mario Capecchi Drive, 
Salt Lake City, UT 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
22 Years of Experience
Expertise in
5
conditions
81 North Mario Capecchi Drive, 
Salt Lake City, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Russell Butterfield is a Pediatric Neurologist in Salt Lake City, Utah. Dr. Butterfield has been practicing medicine for over 22 years is highly rated in 5 conditions, according to our data. His top areas of expertise are Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Spinal Muscular Atrophy (SMA), and Primary Lateral Sclerosis. Dr. Butterfield is currently accepting new patients.

His clinical research consists of co-authoring 74 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Illinois College Of Medicine-Urbana, 2004
Residency
University of Utah Hospitals and Clinics GME
Specialties
Pediatric Neurology
Licenses
Neurology with Special Qualifications in Neurology in UT
Board Certifications
American Board Of Psychiatry And Neurology
Fellowships
University of Utah Hospitals and Clinics GME
Hospital Affiliations
Primary Children's Hospital
Languages Spoken
English
Greek
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Primary Children's Neurology Clinic - Salt Lake City
81 North Mario Capecchi Drive, Salt Lake City, UT 84113
Other Locations
Shriner's Hospital for Children
1275 East Fairfax Road, Salt Lake City, UT 84103
Primary Children's Neurology Clinic - Lehi
2250 North Miller Campus Drive, Lehi, UT 84043

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)
Enrollment Status: Recruiting
Publish Date: April 24, 2025
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
Open-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial
Open-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 03, 2025
Intervention Type: Biological
Study Drug: CAP-1002 Allogeneic Cardiosphere-Derived Cells
Study Phase: Phase 2
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Enrollment Status: Completed
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 3
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Terminated
Publish Date: April 24, 2023
Intervention Type: Biological
Study Phase: Phase 1
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Phase: Phase 2
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
Enrollment Status: Terminated
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Idebenone
Study Phase: Phase 3
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
Enrollment Status: Completed
Publish Date: August 28, 2020
Intervention Type: Drug
Study Phase: Phase 2
Phaseout DMD: A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With Ezutromid in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy (SMT C11005)
Phaseout DMD: A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With Ezutromid in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy (SMT C11005)
Enrollment Status: Terminated
Publish Date: January 02, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 16 Less Clinical Trials

74 Total Publications

A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.
A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophy.
Journal: Expert review of neurotherapeutics
Published: November 13, 2025
Similar Doctors
Expertise in
13
conditions
Dr. Joshua L. Bonkowsky
Pediatric Neurology
Expertise in
13
conditions
Dr. Joshua L. Bonkowsky
Pediatric Neurology

Primary Children's Neurology Clinic - Salt Lake City

81 North Mario Capecchi Drive, 
Salt Lake City, UT 
 (0.7 miles away)
801-213-3599
Experience:
28+ years
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Joshua Bonkowsky is a Pediatric Neurologist in Salt Lake City, Utah. Dr. Bonkowsky has been practicing medicine for over 28 years is highly rated in 13 conditions, according to our data. His top areas of expertise are CACH Syndrome, Adrenoleukodystrophy (ALD), Leukodystrophy, Krabbe Disease, and Gastrostomy. Dr. Bonkowsky is currently accepting new patients.

Expertise in
14
conditions
Dr. Jeffrey J. Ekstrand
Pediatric Neurology | Neurology
Expertise in
14
conditions
Dr. Jeffrey J. Ekstrand
Pediatric Neurology | Neurology
100 Mario Capecchi Dr, 
Salt Lake City, UT 
 (0.8 miles away)
801-587-7575
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jeffrey Ekstrand is a Pediatric Neurologist and a Neurologist in Salt Lake City, Utah. Dr. Ekstrand is highly rated in 14 conditions, according to our data. His top areas of expertise are Seizures, Absence Seizure, Status Epilepticus, and Genetic Epilepsy with Febrile Seizures Plus (GEFS+). Dr. Ekstrand is currently accepting new patients.

Expertise in
1
conditions
Dr. Brandon A. Zielinski
Pediatric Neurology | Pediatrics | Neurology
Expertise in
1
conditions
Dr. Brandon A. Zielinski
Pediatric Neurology | Pediatrics | Neurology
100 Mario Capecchi Dr, 
Salt Lake City, UT 
 (0.8 miles away)
801-587-7575
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brandon Zielinski is a Pediatric Neurologist and a Pediatrics provider in Salt Lake City, Utah. Dr. Zielinski is highly rated in 1 condition, according to our data. His top areas of expertise are Autism Spectrum Disorder, Traumatic Brain Injury, and Fabry Disease. Dr. Zielinski is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Butterfield's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile